Industry news · event 2025-11-06 · 3 min read
The Late-2025 Price Cuts: Zepbound Caps at $449, Wegovy Moves to a Flat $349 (2025)
Under political pressure and pipeline competition, Lilly and Novo reset U.S. self-pay pricing in late 2025 — Zepbound vials $299–$449 via LillyDirect, Wegovy a flat $349 — collapsing the gap compounding was built on.
GRGLP1ProviderCompare Research Team
Pricing & policy research
Quick answerUnder political pressure and pipeline competition, Lilly and Novo reset U.S. self-pay pricing in late 2025 — Zepbound vials $299–$449 via LillyDirect, Wegovy a flat $349 — collapsing the gap compounding was built on.
The most important GLP-1 price event of 2025 came from the manufacturers: in the closing months of the year, Lilly and Novo Nordisk reset U.S. self-pay pricing, and the four-figure list prices that built the compounded market stopped describing what cash payers actually pay.
The structures that emerged are the ones we still verify today: Zepbound through LillyDirect at $299 (2.5 mg), $399 (5 mg), and $449 for every dose from 7.5 to 15 mg — with a ~45-day refill cadence requirement and lapsed-fill repricing of $599–$1,049 — and Wegovy consolidating toward the flat $349-at-every-dose structure NovoCare formalized, later joined by starter-fill and oral-tablet introductory offers.
The arithmetic rewrote every comparison on this site. Against a $1,000+ list price, a $300 compounded program was an obvious call; against $449 FDA-approved maintenance Zepbound, the cheapest verified compounded tirzepatide (NexLife at $215) saves $234/month — real money, but a decision with a genuine other side, priced fully in compounded vs. Zepbound.